Nevro has initiated the U.S. full market launch of its HFX iQ spinal cord stimulation – SCS – system, following the completion of a limited market release. HFX iQ combines clinical inputs, such as pain relief and pain score, along with Quality of Life inputs, such as pain medication and activity level changes, to provide an individualized program setting for each patient. The Senza high-frequency 10 kHz Therapy offers AI-driven iQ modes for treating painful diabetic neuropathy and chronic back and leg pain, including non-surgical back pain. In addition to the U.S. approval for Senza HFX iQ, Nevro has submitted for approval in Europe and Australia.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Nevro still sees 2023 revenue $445M-$455M, consensus $449.24M
- Nevro sees Q1 revenue $94M-$96M, consensus $97.51M
- Nevro reports Q4 EPS (54c), consensus (49c)
- Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
- Nevro price target raised to $72 from $67 at Canaccord